Synapse - Roisin O'Cearbhaill

Results (274)

Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (r/mCC): Phase 1b/2 ENGOT-cx8/GOG-3024/ innovaTV 205 study dose-escalation results

Meeting Abstract

Monk, B.; Van Gorp, T.; Lorusso, D.; O'Cearbhaill, R. E.; Westermann, A.; Banerjee, S.; Collins, D.; Klat, J.; Madsen, K.; Baurain, J. F.; more...
International Journal of Gynecological Cancer (2021)

Fulltext@MSK | Save

Promoting functional persistence in solid tumor CAR T-cell therapy: Mesothelin-targeted CAR (M28z1XXPD1DNR) with T-cell intrinsic PD1 dominant negative receptor

Meeting Abstract

Adusumilli, P. S.; Amador, A. M.; Chintala, N.; Hou, Z.; Offin, M.; Pineda, J.; Senechal, B.; Quach, H. T.; Bellis, R.; Banerjee, S.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Evaluating the role of aromatase inhibitors (AIs) in the treatment of endometrial stromal sarcomas (ESS)

Meeting Abstract

Crowley, F.; Cadoo, K. A.; Chiang, S.; Mueller, J. J.; Hensley, M. L.; O'Cearbhaill, R. E.
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer

Journal Article

Navitski, A.; Al-Rawi, D. H.; Liu, Y.; Rubinstein, M. M.; Friedman, C. F.; Rampal, R. K.; Mandelker, D. L.; Cadoo, K.; O'Cearbhaill, R. E.
Gynecologic Oncology Reports (2021)

Fulltext@MSK | Save

A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab

Journal Article

Adusumilli, P. S.; Zauderer, M. G.; Rivière, I.; Solomon, S. B.; Rusch, V. W.; O'Cearbhaill, R. E.; Zhu, A.; Cheema, W.; Chintala, N. K.; Halton, E.; more...
Cancer Discovery (2021)

Fulltext@MSK | Save

Gavocabtagene autoleucel (gavo-cel, TC-210) dose escalation in refractory mesothelin-expressing solid tumors

Meeting Abstract

Hong, D. S.; SciMentum, S. L.; Tanyi, J.; MacMullen, L.; Jalbert, L.; Muzithras, V. P.; Zikaras, K.; Cao, L.; O'Cearbhaill, R. E.; Quintás-Cardama, A.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study

Meeting Abstract

Vergote, I. B.; Monk, B. J.; O'Cearbhaill, R. E.; Westermann, A. M.; Banerjee, S.; Collins, D. C.; Mirza, M. R.; O'Malley, D.; Gennigens, C.; Pignata, S.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: An MSK Team Ovary phase II study

Journal Article

Zivanovic, O.; Chi, D. S.; Zhou, Q.; Iasonos, A.; Konner, J. A.; Makker, V.; Grisham, R. N.; Brown, A. K.; Nerenstone, S.; Diaz, J. P.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Depletion of high-content CD14(+) cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing